Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTE NASDAQ:CGON NASDAQ:COGT NASDAQ:KALV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$142.01+3.4%$158.17$56.10▼$200.00$5.49B-1.19119,245 shs309,211 shsCGONCG Oncology$61.89-3.7%$67.21$23.65▼$75.50$5.46B0.41818,641 shs1.70 million shsCOGTCogent Biosciences$33.94+3.9%$35.29$4.80▼$43.73$5.58B0.371.54 million shs2.82 million shsKALVKalVista Pharmaceuticals$26.81+0.1%$21.74$9.83▼$26.85$1.43B-0.127.41 million shs8.07 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+3.43%+1.65%-11.94%-24.48%+132.80%CGONCG Oncology-3.67%-2.23%-9.89%+8.60%+143.28%COGTCogent Biosciences+3.89%+8.61%-7.80%-15.09%+604.15%KALVKalVista Pharmaceuticals+0.07%+0.20%+36.58%+70.11%+133.74%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$142.01+3.4%$158.17$56.10▼$200.00$5.49B-1.19119,245 shs309,211 shsCGONCG Oncology$61.89-3.7%$67.21$23.65▼$75.50$5.46B0.41818,641 shs1.70 million shsCOGTCogent Biosciences$33.94+3.9%$35.29$4.80▼$43.73$5.58B0.371.54 million shs2.82 million shsKALVKalVista Pharmaceuticals$26.81+0.1%$21.74$9.83▼$26.85$1.43B-0.127.41 million shs8.07 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+3.43%+1.65%-11.94%-24.48%+132.80%CGONCG Oncology-3.67%-2.23%-9.89%+8.60%+143.28%COGTCogent Biosciences+3.89%+8.61%-7.80%-15.09%+604.15%KALVKalVista Pharmaceuticals+0.07%+0.20%+36.58%+70.11%+133.74%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 2.63Moderate Buy$203.0042.95% UpsideCGONCG Oncology 2.71Moderate Buy$81.7332.05% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.7328.84% UpsideKALVKalVista Pharmaceuticals 2.22Hold$30.6014.14% UpsideCurrent Analyst Ratings BreakdownLatest KALV, CGON, COGT, and BLTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026BLTEBelite Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$223.00 ➝ $215.005/22/2026BLTEBelite Bio Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$217.005/22/2026BLTEBelite Bio BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026BLTEBelite Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$200.005/19/2026CGONCG Oncology Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform5/18/2026CGONCG Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$100.005/14/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$77.00 ➝ $82.005/11/2026CGONCG Oncology JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$91.00 ➝ $96.005/11/2026CGONCG Oncology Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$79.00 ➝ $81.005/11/2026CGONCG Oncology Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$75.00 ➝ $77.005/11/2026CGONCG Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $80.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$19.91 per shareN/ACGONCG Oncology$5.07M1,076.48N/AN/A$12.38 per share5.00COGTCogent BiosciencesN/AN/AN/AN/A$3.18 per shareN/AKALVKalVista Pharmaceuticals$1.43M1,000.98N/AN/A($0.37) per share-72.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$77.61M-$2.53N/A118.34N/AN/A-13.14%-12.88%8/10/2026 (Estimated)CGONCG Oncology-$160.99M-$2.33N/AN/AN/AN/A-23.33%-22.24%8/7/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)KALVKalVista Pharmaceuticals-$109.52M-$3.46N/A45.44N/AN/A-341.44%-111.94%8/13/2026 (Estimated)Latest KALV, CGON, COGT, and BLTE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q1 2026BLTEBelite Bio-$0.60-$0.34+$0.26-$0.68N/AN/A5/14/2026Q1 2026KALVKalVista Pharmaceuticals-$0.3763-$0.43-$0.0538-$0.43$39.03 million$39.17 million5/8/2026Q1 2026CGONCG Oncology-$0.58-$0.71-$0.13-$0.71$0.45 million$1.08 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A3/2/2026Q4 2025BLTEBelite Bio-$0.56-$0.38+$0.18-$0.70N/AN/A2/27/2026Q4 2025CGONCG Oncology-$0.61-$0.51+$0.10-$0.51N/A$2.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/ACGONCG OncologyN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AKALVKalVista PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A33.7133.71CGONCG OncologyN/A31.3031.25COGTCogent Biosciences0.4115.1415.14KALVKalVista Pharmaceuticals8.185.175.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%CGONCG Oncology26.56%COGTCogent BiosciencesN/AKALVKalVista PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%CGONCG Oncology4.80%COGTCogent Biosciences7.29%KALVKalVista Pharmaceuticals4.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1039.97 million34.65 millionNot OptionableCGONCG Oncology6188.20 million83.97 millionOptionableCOGTCogent Biosciences80170.87 million158.41 millionOptionableKALVKalVista Pharmaceuticals10053.24 million50.95 millionOptionableKALV, CGON, COGT, and BLTE HeadlinesRecent News About These CompaniesKalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,926 Shares of Stock2 hours ago | americanbankingnews.comKalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,489 Shares2 hours ago | insidertrades.comBlue Owl Capital Holdings LP Increases Position in KalVista Pharmaceuticals, Inc. $KALVMay 25 at 3:36 AM | marketbeat.comUBS Group AG Sells 82,155 Shares of KalVista Pharmaceuticals, Inc. $KALVMay 21, 2026 | marketbeat.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Hold" from BrokeragesMay 21, 2026 | americanbankingnews.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of "Hold" from BrokeragesMay 21, 2026 | marketbeat.comKalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALVMay 19, 2026 | businesswire.comKalVista Pharmaceuticals (NASDAQ:KALV) Sees Strong Trading Volume - Time to Buy?May 17, 2026 | americanbankingnews.comMerger Agreement With Chiesi Puts Strategic Handcuffs on KalVista, Raising Execution and Liquidity RisksMay 16, 2026 | tipranks.comKalVista Pharmaceuticals (KALV) price target decreased by 12.99% to 30.47May 15, 2026 | msn.comInsider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells 3,322 Shares of StockMay 14, 2026 | insidertrades.comA Look At KalVista Pharmaceuticals (KALV) Valuation After A Strong Year Of Share Price GainsMay 10, 2026 | finance.yahoo.comF m Investments LLC Purchases 37,486 Shares of KalVista Pharmaceuticals, Inc. $KALVMay 10, 2026 | marketbeat.comItaly's Angelini to buy Catalyst Pharma for $4.1 billion in US market expansionMay 7, 2026 | msn.comKalVista Pharmaceuticals (NASDAQ:KALV) Reaches New 1-Year High - Here's WhyMay 6, 2026 | marketbeat.comHC Wainwright & Co. downgrades KalVista Pharmaceuticals (KALV)May 2, 2026 | msn.comKalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALVMay 1, 2026 | businesswire.comKalVista Pharmaceuticals (NASDAQ:KALV) Rating Lowered to "Neutral" at HC WainwrightMay 1, 2026 | marketbeat.comKALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its ShareholdersMay 1, 2026 | tmcnet.comChiesi widens rare disease portfolio with $1.9bn KalVista buyoutMay 1, 2026 | msn.comKalVista scores $1.9 billion takeover deal; why a key rival jumped tooMay 1, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALV, CGON, COGT, and BLTE Company DescriptionsBelite Bio NASDAQ:BLTE$142.01 +4.71 (+3.43%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$142.94 +0.93 (+0.65%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.CG Oncology NASDAQ:CGON$61.89 -2.36 (-3.67%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$61.63 -0.26 (-0.42%) As of 07:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.Cogent Biosciences NASDAQ:COGT$33.94 +1.27 (+3.89%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$33.83 -0.11 (-0.33%) As of 07:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.KalVista Pharmaceuticals NASDAQ:KALV$26.81 +0.02 (+0.07%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$26.77 -0.04 (-0.15%) As of 07:27 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
